Lipanthyl Micronised (Fenofibrate Micronised)

Fenofibrate, the active ingredient in Lipanthyl Micronised, is a fibrate presented as a micronised tablet for oral use. It is indicated for the management of hypertriglyceridaemia, mixed dyslipidaemia and as adjunct therapy in primary hypercholesterolaemia in adult patients.

GNH USA supplies Lipanthyl Micronised as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, manufactured under EU GMP standards and ensuring quality and regulatory conformity across EU and global markets.

Lipanthyl Micronised (fenofibrate) is used to treat disorders of lipid metabolism.

- Hypertriglyceridaemia: lowers elevated serum triglyceride concentrations, helping to reduce the risk of pancreatitis. - Mixed dyslipidaemia: decreases triglycerides and low‑density lipoprotein (LDL) cholesterol while modestly increasing high‑density lipoprotein (HDL) cholesterol, supporting a more favorable lipid profile. - Primary hypercholesterolaemia (as adjunct therapy): used alongside statins to further improve lipid parameters, particularly triglycerides and HDL‑cholesterol.

Fenofibrate may be associated with a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: transient increase in ALT/AST. - Muscle pain: mild myalgia without weakness. - Headache: occasional tension‑type headache. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: muscle breakdown with markedly elevated creatine kinase. - Severe liver injury: hepatitis or hepatic failure. - Acute renal failure: sudden decrease in kidney function.

Before prescribing Lipanthyl Micronised, clinicians should consider several precautionary measures to minimise risk.

- Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal function assessment: evaluate serum creatinine and eGFR before initiation. - Muscle toxicity vigilance: monitor for unexplained muscle pain or weakness, especially with statins. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk. - Drug interactions: review concomitant medications that may increase risk of myopathy or affect fenofibrate levels. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Fenofibrate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis. - Cyclosporine: elevated fenofibrate plasma concentrations. - Anticoagulants (warfarin): potentiation of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Bile acid sequestrants (cholestyramine): reduced absorption of fenofibrate. - Gemfibrozil: additive risk of muscle toxicity. - Oral contraceptives: possible increase in triglyceride levels.